Literature DB >> 2905151

Ebastine: the effect of a new antihistamine on psychomotor performance and autonomic responses in healthy subjects.

J Vincent1, D J Sumner, J L Reid.   

Abstract

1. Ebastine, through its carboxylic acid metabolite has antihistamine (H1-receptor) activity in man. 2. We have examined in a single blind placebo controlled study the effects of 10 mg and 50 mg of ebastine on cardiovascular, autonomic and psychomotor function in healthy subjects. 3. Ebastine had no effect on blood pressure or heart rate and there was no evidence of any anticholinergic activity on circulatory reflexes or salivation. 4. Ebastine did not impair psychomotor performance as assessed by critical flicker fusion at either dose. 5. Ebastine 10 mg had no effect on sedation measured by visual analogue scale or direct questioning, however ebastine 50 mg did cause a modest increase in indices of sedation. 6. Ebastine did not have detectable sedative properties at the 10 mg dose where long-lasting antihistamine effects can be demonstrated.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2905151      PMCID: PMC1386626          DOI: 10.1111/j.1365-2125.1988.tb05289.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  20 in total

1.  Clinical pharmacology and pharmacokinetics of clonidine.

Authors:  C T Dollery; D S Davies; G H Draffan; H J Dargie; C R Dean; J L Reid; R A Clare; S Murray
Journal:  Clin Pharmacol Ther       Date:  1976-01       Impact factor: 6.875

2.  Critical flicker frequency (CFF) and psychotropic drugs in normal human subjects-a review.

Authors:  J M Smith; H Misiak
Journal:  Psychopharmacologia       Date:  1976-05-28

3.  The pharmacokinetics, antihistamine and concentration-effect relationship of ebastine in healthy subjects.

Authors:  J Vincent; R Liminana; P A Meredith; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1988-11       Impact factor: 4.335

4.  Performance studies with antihistamines.

Authors:  C H Clarke; A N Nicholson
Journal:  Br J Clin Pharmacol       Date:  1978-07       Impact factor: 4.335

5.  Correlation between plasma diphenhydramine level and sedative and antihistamine effects.

Authors:  S G Carruthers; D W Shoeman; C E Hignite; D L Azarnoff
Journal:  Clin Pharmacol Ther       Date:  1978-04       Impact factor: 6.875

6.  A repeated dose comparison of the side effects of five antihistamines on objective assessments of psychomotor performance, central nervous system arousal and subjective appraisals of sleep and early morning behaviour.

Authors:  I Hindmarch; A C Parrott
Journal:  Arzneimittelforschung       Date:  1978

7.  Critical flicker frequency and centrally-acting drugs.

Authors:  P Turner
Journal:  Br J Ophthalmol       Date:  1968-03       Impact factor: 4.638

Review 8.  Psychomotor function and psychoactive drugs.

Authors:  I Hindmarch
Journal:  Br J Clin Pharmacol       Date:  1980-09       Impact factor: 4.335

9.  A comparison of triprolidine and clemastine on histamine antagonism and performance tests in man: implications for the mechanism of drug induced drowsiness.

Authors:  A W Peck; A S Fowle; C Bye
Journal:  Eur J Clin Pharmacol       Date:  1975-08-14       Impact factor: 2.953

10.  Autonomic control of the immediate heart rate response to lying down.

Authors:  F Bellavere; D J Ewing
Journal:  Clin Sci (Lond)       Date:  1982-01       Impact factor: 6.124

View more
  12 in total

1.  Comparative clinical studies with ebastine: efficacy and tolerability.

Authors:  X Luria
Journal:  Drug Saf       Date:  1999       Impact factor: 5.606

2.  The pharmacokinetics, antihistamine and concentration-effect relationship of ebastine in healthy subjects.

Authors:  J Vincent; R Liminana; P A Meredith; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1988-11       Impact factor: 4.335

Review 3.  Pharmacokinetic optimisation of histamine H1-receptor antagonist therapy.

Authors:  F E Simons; K J Simons
Journal:  Clin Pharmacokinet       Date:  1991-11       Impact factor: 6.447

Review 4.  The antihistamines of the nineties.

Authors:  M M Janssens; P H Howarth
Journal:  Clin Rev Allergy       Date:  1993

Review 5.  Comparative tolerability of second generation antihistamines.

Authors:  F Horak; U P Stübner
Journal:  Drug Saf       Date:  1999-05       Impact factor: 5.606

Review 6.  Ebastine. a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders.

Authors:  L R Wiseman; D Faulds
Journal:  Drugs       Date:  1996-02       Impact factor: 9.546

7.  Differential cognitive effects of ebastine and (+)-chlorpheniramine in healthy subjects: correlation between cognitive impairment and plasma drug concentration.

Authors:  Masaaki Tagawa; Michiko Kano; Nobuyuki Okamura; Makoto Higuchi; Michiaki Matsuda; Yasuyuki Mizuki; Hiroyuki Arai; Toshihiko Fujii; Sadao Komemushi; Masatoshi Itoh; Hidetada Sasaki; Takehiko Watanabe; Kazuhiko Yanai
Journal:  Br J Clin Pharmacol       Date:  2002-03       Impact factor: 4.335

8.  Lack of pharmacodynamic and pharmacokinetic interactions of the antihistamine ebastine with ethanol in healthy subjects.

Authors:  M J Mattila; T Kuitunen; Y Plétan
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

9.  Diazepam effects on the performance of healthy subjects are not enhanced by treatment with the antihistamine ebastine.

Authors:  M J Mattila; K Aranko; T Kuitunen
Journal:  Br J Clin Pharmacol       Date:  1993-03       Impact factor: 4.335

Review 10.  H1-receptor antagonists. Comparative tolerability and safety.

Authors:  F E Simons
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.